NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!
Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.
Start Free »

PACB | NASDAQ

$2.37 $0.54 | 29.51%
SIGNAL:Signal available — unlock to view |2026-09-22 |F&G 45 |RSI 84.6

Company Overview:

Market Cap: $736.25M
Trailing PE: N/A
FWD PE: —
Payout Ratio (TTM): —
52-Week Range: $1.07 - $2.73

10 Year PACB Performance Metrics:

Total Return (with DRIP): -73.4% (-12.40% CAGR)
Total Return (no DRIP): -73.4% (-12.40% CAGR)
Share Price: -73.5% (-12.45% CAGR)
Yield on Cost (with DRIP): —
Total Invested: $10,000
Total Value (with DRIP): $2,660
Total Return $ (with DRIP): -$7,340
PACB Total Return
1M 3M 6M YTD 1Y 3Y 5Y 10Y
PACB Price Chart
1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

PACB Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

PACB - Revenue
PACB Revenue CAGR:1Y: -1.91%2Y: 4.07%5Y: 4.97%10Y: 6.52%
PACB - Earnings Per Share (EPS)
PACB EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
PACB - Net Income
PACB Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
PACB - EBITDA
PACB EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
PACB - Free Cash Flow
PACB Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
PACB - Free Cash Flow / Share
PACB Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
PACB - Operating Income
PACB Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
PACB - Gross Profit
PACB Gross Profit CAGR:1Y: -13.93%2Y: 45.89%5Y: -1.68%10Y: 1.73%
PACB - Shares Outstanding
PACB Shares Outstanding CAGR:1Y: 3.41%2Y: 6.75%5Y: 9.35%10Y: 13.42%
PACB - Share Buybacks
PACB Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
PACB - Stock-Based Comp
PACB Stock-Based Comp CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 10.54%
PACB - Expenses
PACB Expenses CAGR:1Y: 736.00%2Y: 76.32%5Y: 23.99%10Y: 5.09%
PACB - Revenue by Segment
PACB Revenue CAGR:1Y: -1.91%2Y: 4.07%5Y: 4.97%10Y: 6.52%
PACB - Revenue by Region
PACB Revenue CAGR:1Y: -1.91%2Y: 4.07%5Y: 4.97%10Y: 6.52%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

PACB - REVENUE: Actual + Estimates
PACB Actual Revenue CAGR:1Y: -1.91%2Y: 4.07%5Y: 4.97%10Y: 6.52%
PACB - EPS: Actual + Estimates
PACB Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
PACB - NET INCOME: Actual + Estimates
PACB Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
PACB - EBITDA: Actual + Estimates
PACB Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

PACB - Net Profit Margin
PACB Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
PACB - Gross Profit Margin
PACB Gross Profit Margin CAGR:1Y: -12.27%2Y: 40.17%5Y: -6.33%10Y: -4.49%
PACB - Price to Earnings
PACB Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
PACB - Price To Sales Ratio
PACB Price To Sales Ratio CAGR:1Y: 42.95%2Y: 21.41%5Y: -43.04%10Y: -7.72%
PACB - Return on Capital Employed
PACB Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
PACB - Return on Invested Capital
PACB Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Compare stocks side-by-side

Projected Future Returns & Dividends for PACB

Based on past 10-year performance, here are PACB growth metrics:

Share price CAGR of -12.45%
Dividend CAGR of +0%

Using PACB CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

PACB (DRIP)PACB - No DRIP
Current Price$2.37$2.37
Start Shares4,219.414,219.41
Start Value$10,000$10,000
  
After 10 years:
Final Share Count4,219.414,219.41
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$0.63$2.37
Total Dividends$0$0
Final Value$2,645$10,000

Estimated Future Value + Dividends - PACB

NOTE: Above numbers are our estimate based on PACB's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

Company Info

Pacific Biosciences of California, Inc. (PACB) had its IPO on 2010-10-27, and is traded on NASDAQ stock exchange.

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.

PACB website: https://www.pacb.com


Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)
Loading signals…

DCF Model — PACB

Value from:
Pay up to today
—
vs current price $2.37
—
Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
YearFCFImplied price
Sensitivity — fair value: growth ↓ × target return →